Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Arvinas IncARVN-4.4414.692.25-0.62-59.16%-12.68%59.80$25.32$32.1328,093$19.06

Detail of Arvinas Inc

 
CEO
Dr. John G. Houston Ph.D.
Employees
280
Industry
Biotechnology
Sector
Healthcare
Market cap
$1B

Company details

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

Revenue
Revenue (Rev)
$93.30M
Arvinas Inc
ARVN • XNGS • US
$19.06
-22.03 (-53.61%)
Stock vs Industry average
  • Industry average

Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$4.29
Margin profit
-191.56%
52 week low
$18.715
52 week high
$52.310001
50-day simple moving average
$24.13
200-day simple moving average
$25.32
Percent held by insiders
7.22%
Percent held by institutions
109.23%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Insider Trading

Comparison of selected companies

 
%
Price change
ARVN -54.97%
eps change
ARVN 0.00%